Abstract:PURPOSE:Cisplatin can cause a variety of DNA crosslink lesions including intra-strand and inter-strand crosslinks (ICLs), which are associated with the sensitivity of cancer cells to cisplatin. Here, we aimed to assess the contribution of the Fanconi anemia (FA), homologous recombination (HR) and nucleotide excision repair (NER) pathways to cisplatin resistance in non-small cell lung cancer (NSCLC)-derived cells.METHODS:The expression of FA, HR and NER pathway-associated genes was assessed by RT-qPCR and Western blotting. siRNAs were used to knock down the expression of these genes. CCK-8 and flow cytometry assays were used to assess the viability and apoptotic rate of NSCLC-derived cells, respectively. Immunofluorescence and alkaline comet assays were used to assess the repair of ICLs.RESULTS:We found that acquired cisplatin-resistant NSCLC-derived A549/DR cells exhibited markedly enhanced FA and HR repair pathway capacities compared to its parental A549 cells and another independent NSCLC-derived cell line, Calu-1, which possesses a moderate innate resistance to cisplatin. siRNA-mediated silencing of the FA-associated genes FANCL and RAD18 and the HR-associated genes BRCA1 and BRCA2 significantly potentiated the sensitivity of A549/DR cells to cisplatin compared to A549 and Calu-1 cells, suggesting that the acquired cisplatin resistance in A549/DR cells may be attributed to enhanced FA and HR pathway capacities responsible for ICL repair. Although we found that expression knockdown of the NER-associated genes XPA and ERCC1 sensitized the three NSCLC-derived cell lines to cisplatin, the sensitization effect was more significant in Calu-1 cells than in A549 and A549/DR cells, implying that the innate cisplatin resistance in Calu-1 cells may result from an increased NER activity.CONCLUSIONS:Our results indicate that the functional status of DNA repair pathways determine the sensitivity of NSCLC cells to cisplatin. Direct targeting of the pathway that is involved in cisplatin resistance may be an effective strategy to surmount cisplatin resistance in NSCLC.

DNA Repair and Resistance of Lung Cancer to Cisplatin

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

DNA repair pathways and cisplatin resistance: an intimate relationship

Role of Nucleotide Excision Repair in Cisplatin Resistance

The Functional Status of DNA Repair Pathways Determines the Sensitization Effect to Cisplatin in Non-Small Cell Lung Cancer Cells.

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

Molecular mechanisms of cisplatin resistance

Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy

Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution

Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment

Identification of Genes Associated with Cisplatin Resistance in Human Oral Squamous Cell Carcinoma Cell Line

Effects of Cisplatin on Expression of DNA Repair Genes:MGMT and DNA-PKcs in A549 Cells

Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non‑small cell lung cancer cell lines

Transcriptome Sequencing Reveals Key Pathways And Genes Associated With Cisplatin Resistance In Lung Adenocarcinoma A549 Cells

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Integrated Analysis of DNA Methylation and Mrna Expression Profiling Reveals Candidate Genes Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer.

New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment

DNA Damage Responsive Mir-33B-3p Promoted Lung Cancer Cells Survival and Cisplatin Resistance by Targeting P21waf1/cip1

Effects of cisplatin on the expression of genes involved in DNA damage response in human lung cancer cell line LTEP-a-2

Exploring the mechanism of cisplatin resistance by transcriptome sequencing and reversing the chemoresistance by autophagy inhibition in small cell lung cancer

Pathogenesis and Therapeutic Strategy in Platinum Resistance Lung Cancer